← Back to Search

Lenalidomide + Rituximab for Non-Hodgkin's Lymphoma (MAGNIFY Trial)

Phase 3
Waitlist Available
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) Performance status < 2
Age ≥18 years
Must not have
Any medical condition (other than the underlying lymphoma) that requires chronic steroid use
Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing the combination of lenalidomide and rituximab to see if it is more effective in treating NHL than lenalidomide alone.

Who is the study for?
Adults with certain types of B-cell Non-Hodgkin's Lymphoma, specifically Follicular, Marginal Zone or Mantle Cell Lymphoma that has returned or didn't respond to treatment. Participants need measurable disease, good performance status (<2), and adequate bone marrow function. They must not have used lymphoma therapy recently and should agree to pregnancy precautions.
What is being tested?
The trial is testing the effectiveness of Lenalidomide combined with Rituximab (R2) against these lymphomas compared to using Rituximab alone for maintenance. It explores whether R2 can improve outcomes in patients whose disease has relapsed or is refractory.
What are the potential side effects?
Lenalidomide may cause blood clots, fatigue, diarrhea, itching/rash; while Rituximab could lead to infusion reactions like fever/chills, infections risk increase due to low white blood cells count and potential heart issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can do all or most of my daily activities without help.
Select...
I am 18 years old or older.
Select...
My cancer has returned or worsened after my last treatment.
Select...
My diagnosis is a specific type of lymphoma.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am on long-term steroids for a condition other than lymphoma.
Select...
My lymphoma is not follicular, marginal zone, or Grade 3b.
Select...
I have taken less than 20 mg/day of prednisone or equivalent in the last week.
Select...
My lymphoma has affected or previously affected my brain or spinal cord.
Select...
I am at risk for blood clots and refuse to take preventive medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL)
Secondary study objectives
Adverse Events
Complete response rate
Duration of complete response
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A: Lenalidomide + rituximab followed by lenalidomideExperimental Treatment2 Interventions
Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but \< 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m\^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by an optional Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
Group II: Arm B: Lenalidomide + rituximab followed by rituximabActive Control2 Interventions
Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m\^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenalidomide
2005
Completed Phase 3
~2240
Rituximab
1999
Completed Phase 4
~2990

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor
645 Previous Clinical Trials
129,937 Total Patients Enrolled
Mecide Gharibo, MDStudy DirectorCelgene
2 Previous Clinical Trials
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,567 Previous Clinical Trials
3,383,759 Total Patients Enrolled

Media Library

Lenalidomide Clinical Trial Eligibility Overview. Trial Name: NCT01996865 — Phase 3
Non-Hodgkin's Lymphoma Research Study Groups: Arm A: Lenalidomide + rituximab followed by lenalidomide, Arm B: Lenalidomide + rituximab followed by rituximab
Non-Hodgkin's Lymphoma Clinical Trial 2023: Lenalidomide Highlights & Side Effects. Trial Name: NCT01996865 — Phase 3
Lenalidomide 2023 Treatment Timeline for Medical Study. Trial Name: NCT01996865 — Phase 3
~43 spots leftby Nov 2025